Skip to content
10-Q

Quarterly Report

EVOKE PHARMA, INC.

0000950170-25-070401

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 1.49M sh
Shares Diluted Q1 2025 · Mar 31, 2025 2.55M sh
Shares Diluted restated Q1 2025 · Mar 31, 2024 756.81K sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$997.51K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$2.58M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $12.62M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $13.6M
Stockholders Equity Q1 2025 · Mar 31, 2025 $5.84M
Stockholders Equity Q1 2025 · Dec 31, 2024 $7.04M
Stockholders Equity Q1 2025 · Mar 31, 2024 $3.5M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$2.58M
Current Liabilities Q1 2025 · Mar 31, 2025 $10.45M
Current Liabilities Q1 2025 · Dec 31, 2024 $10.38M
Total Liabilities Q1 2025 · Mar 31, 2025 $10.53M
Total Liabilities Q1 2025 · Dec 31, 2024 $10.48M
Current Assets Q1 2025 · Mar 31, 2025 $16.23M
Current Assets Q1 2025 · Dec 31, 2024 $17.24M
Total Assets Q1 2025 · Mar 31, 2025 $16.38M
Total Assets Q1 2025 · Dec 31, 2024 $17.52M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.51
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$2.09
Eps Basic Q1 2025 · Mar 31, 2025 −$0.51
Eps Basic restated Q1 2025 · Mar 31, 2024 −$2.09
Sga Expense Q1 2025 · Mar 31, 2025 $4.3M
Sga Expense Q1 2025 · Mar 31, 2024 $3.14M
Net Income Q1 2025 · Mar 31, 2025 −$1.31M
Net Income Q1 2025 · Mar 31, 2024 −$1.58M
Net Income Q1 2025 · Jun 30, 2023 −$1.58M
Operating Income Q1 2025 · Mar 31, 2025 −$1.3M
Operating Income Q1 2025 · Mar 31, 2024 −$1.5M
Revenue Q1 2025 · Mar 31, 2025 $3.08M
Revenue Q1 2025 · Mar 31, 2024 $1.74M